This question tests the appropriate medication for renal protection in diabetic kidney disease. Key patient-specific factors include albuminuria 220 mg/g, type 2 diabetes, and BP 138/84 mmHg near goal. The best choice is lisinopril, as ADA guidelines recommend ACE inhibitors to slow progression via antiproteinuric effects. Option B lacks renoprotection; option C may worsen; option D is central-acting. These distractors ignore evidence for RAAS inhibition. A pearl is to target ACR <30 mg/g with therapy. Framework: Prioritize ACEI/ARB in proteinuric DKD regardless of BP.

This question tests appropriate apixaban dosing for stroke prevention in nonvalvular atrial fibrillation with renal impairment. Key patient-specific factors include severe renal impairment (CrCl 22 mL/min), age 58 years, weight 74 kg, and absence of other dose-reduction criteria. Apixaban 5 mg PO twice daily is correct because the patient meets only ONE of the three criteria for dose reduction (age ≥80 years, weight ≤60 kg, or SCr ≥1.5 mg/dL) - her SCr is 2.6 mg/dL. Apixaban requires dose reduction to 2.5 mg twice daily only when TWO or more criteria are met. Choice A (10 mg twice daily for 7 days) is the treatment dose for acute VTE, not atrial fibrillation stroke prevention. Choices B and D represent inappropriate dose reductions since only one criterion is met. The clinical pearl is that apixaban dose reduction for atrial fibrillation requires meeting at least TWO of three specific criteria, unlike other DOACs which may have different renal cutoffs, and severe renal impairment alone (even with CrCl <25 mL/min) does not automatically mandate dose reduction if other criteria are absent.

This question tests recognition of drug interactions requiring monitoring or dose adjustment. The key interaction is between amoxicillin/clavulanate and warfarin, which can increase INR and bleeding risk through multiple mechanisms including disruption of gut flora that produce vitamin K. Warfarin dose may need adjustment and closer INR monitoring is required during and after antibiotic therapy, making choice B correct. Choice A is incorrect because amoxicillin/clavulanate does not require renal dose adjustment until CrCl <30 mL/min, and this patient's CrCl is approximately 75 mL/min (using Cockcroft-Gault: (140-63)×82×0.85/(72×0.9)). Choice C is incorrect as sertraline dose adjustment is not required solely due to concurrent warfarin use, though both can increase bleeding risk. Choice D is incorrect because levothyroxine does not need to be held during antibiotic therapy; any interaction affecting absorption can be managed by consistent administration timing. The clinical pearl is that many antibiotics, including amoxicillin/clavulanate, can potentiate warfarin's effect requiring increased INR monitoring frequency during and for several days after antibiotic completion.

This question tests the appropriate empiric antibiotic selection for complicated urinary tract infection (UTI) in males. Key patient-specific factors include male gender (all UTIs in males are considered complicated), sulfonamide allergy (eliminating trimethoprim-sulfamethoxazole), and reduced renal function (CrCl 45 mL/min, which contraindicates nitrofurantoin). Ciprofloxacin 500 mg PO twice daily for 7 days is the best choice as it provides appropriate coverage for complicated UTI pathogens, achieves adequate urinary concentrations despite moderate renal impairment, and avoids the patient's sulfa allergy. Nitrofurantoin (choice B) is contraindicated when CrCl <60 mL/min due to inadequate urinary drug concentrations and increased toxicity risk. Trimethoprim-sulfamethoxazole (choice C) is contraindicated due to the patient's sulfonamide allergy history of hives. Doxycycline (choice D) has poor urinary penetration and is not recommended for UTI treatment. The clinical pearl is that all UTIs in males are considered complicated and require longer treatment durations (7-14 days) compared to uncomplicated UTIs in females, and renal function must be assessed before selecting antibiotics like nitrofurantoin.

This question tests the appropriate initial dosing for venlafaxine XR in major depressive disorder. Key patient-specific factors include inadequate response to sertraline, normal labs, and adult status. The best choice is venlafaxine XR 37.5 mg PO daily, as APA guidelines and labeling recommend starting low and titrating to minimize side effects like hypertension. Option B starts too high; option C exceeds daily max; option D uses IR form incorrectly. These distractors ignore titration needs. A pearl is to monitor BP during SNRI initiation. Framework: Escalate antidepressants gradually, assessing response every 4-6 weeks.

This question tests appropriate management of supratherapeutic INR on warfarin without bleeding. Key patient-specific factors include INR 4.8 (goal 2-3), no bleeding, stable Hgb, and amiodarone interaction potentiating warfarin. The best choice is to hold 1-2 doses and resume at lower weekly dose with recheck in 1 week, per ACCP guidelines for minor elevations to safely lower INR without over-correction. Option A ignores elevation, risking bleed; option C uses vitamin K unnecessarily for asymptomatic cases; option D stops permanently, inappropriate for AF. These distractors over- or under-react to INR. A pearl is to adjust warfarin by 10-20% weekly for deviations. Framework: Use INR trends and factors like drugs/diet for dose decisions.

This question tests the appropriate dosing regimen for apixaban in stroke prevention for nonvalvular atrial fibrillation (NVAF). Key patient-specific factors include age 59 years, weight 70 kg, SCr 1.6 mg/dL with CrCl 28 mL/min, and concomitant amiodarone, a P-gp inhibitor that may increase apixaban exposure. The best choice is apixaban 5 mg PO twice daily, as ARISTOTLE trial guidelines and labeling recommend the standard dose unless two of three criteria (age ≥80, weight ≤60 kg, SCr ≥1.5 mg/dL) are met for dose reduction, and here only one criterion (SCr) applies despite renal impairment and drug interaction. Option A is the loading regimen for VTE treatment, not indicated for NVAF; option B applies the reduced dose incorrectly without meeting criteria; option D halves the frequency inappropriately, risking subtherapeutic levels. These distractors reflect errors in applying dose reduction criteria or confusing indications. A transferable pearl is to use the ABC criteria (age, body weight, creatinine) for apixaban dosing in NVAF, avoiding automatic reductions for isolated factors. For similar anticoagulants, always check for drug interactions via P-gp/CYP3A4 and adjust per product labeling.

This question tests the appropriate dosing regimen for doxycycline in outpatient community-acquired pneumonia (CAP). Key patient-specific factors include age 71 years, penicillin allergy, eGFR 58 mL/min/1.73 m² allowing standard dosing, and non-ICU status. The best choice is doxycycline 100 mg PO twice daily for 5-7 days, as IDSA/ATS guidelines endorse this for outpatient CAP in adults with beta-lactam allergies, providing coverage for atypical pathogens. Option B under-doses and shortens duration, risking failure; option C uses excessive dose and duration; option D reduces frequency inappropriately. These distractors reflect errors in duration and frequency for respiratory infections. A pearl is to tailor CAP therapy duration to clinical response, minimum 5 days. Framework: Consider comorbidities, allergies, and local resistance when selecting antibiotics for CAP.

This question tests the appropriate dosing regimen for nitrofurantoin in the treatment of uncomplicated urinary tract infection (UTI) in a male patient. Key patient-specific factors include age 67 years, male gender, eGFR 38 mL/min/1.73 m² indicating moderate renal impairment, and allergy to TMP-SMX limiting alternative options. The best choice is nitrofurantoin 100 mg PO twice daily for 5 days, as IDSA guidelines recommend this regimen for uncomplicated cystitis in adults when susceptibility is likely and renal function permits, with evidence supporting efficacy in males for 5-7 days despite traditional views of male UTIs as complicated. Option A uses a lower dose and shorter duration more suited for older formulations or pediatric use, making it suboptimal for efficacy; option C extends to 10-14 days, which is reserved for complicated UTIs or pyelonephritis; option D employs a prophylactic dose inadequate for acute treatment. These distractors highlight misconceptions about duration in uncomplicated vs. complicated infections and formulation-specific dosing. A clinical pearl is to always assess renal function before nitrofurantoin use, avoiding it if CrCl <30 mL/min due to risk of subtherapeutic levels and toxicity. For similar decisions, calculate eGFR and consider gender-specific UTI classification per AUA guidelines to guide duration.

This question tests the appropriate initial dosing for chlorthalidone in hypertension. Key patient-specific factors include new diagnosis, normal electrolytes/renal function, and BP 152/94 mmHg requiring therapy. The best choice is chlorthalidone 12.5 mg PO daily, as ACC/AHA guidelines recommend starting low (12.5-25 mg) for thiazides to minimize electrolyte disturbances while controlling BP. Option B overdoses at 100 mg; option C uses excessive frequency; option D under-doses at 2.5 mg. These distractors misapply dosing ranges. A pearl is to monitor potassium and renal function post-initiation. Framework: Titrate antihypertensives based on BP response and tolerability.